Amyloid imaging of Lewy body-associated disorders

Movement Disorders

Volumn 25, Issue 15, 2010, Pages 2516-2523

  Foster, Erin R ^a,d   Campbell, Meghan C ^a   Burack, Michelle A ^b   Hartlein, Johanna ^a   Flores, Hubert P ^a   Cairns, Nigel J ^a   Hershey, Tamara ^a,c   Perlmutter, Joel S ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Dementia with Lewy bodies; Parkinson's disease; Parkinson's disease with dementia; PET

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; PERGOLIDE; PITTSBURGH COMPOUND B; PITTSBURGH COMPOUND B C 11; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; ROPINIROLE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; BINDING AFFINITY; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; CLINICAL EXAMINATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; COGNITION; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; THIAZOLES;

EID: 78349250530     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23393     Document Type: Article

References (37)

1. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 2003; 18(suppl 6): S63-S71.
2. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707; quiz 1837.
3. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
4. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
5. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58: 773-776.
6. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-112.
7. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67: 1931-1934.
8. Masliah E, Rockenstein E, Veinbergs I, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98: 12245-12250.
9. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26: 1183-1192.
10. Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-10371.
11. Ye L, Velasco A, Fraser G, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 2008; 105: 1428-1437.
12. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74: 77-84.
13. 11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
14. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-910.
15. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107-112.
16. Racette BA, Rundle M, Parsian A, Perlmutter JS. Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. Am J Med Genet 1999; 88: 539-543.
17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
18. Fahn S, Elton RL, Members of the UDC, Marsden CD, Goldstein M, Calne DB. Unified Parkinson's Disease Rating Scale. In: Recent developments in Parkinson's disease. New York: Macmillan; 1987. p 153-163.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
20. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181-187.
21. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49.
22. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-239.
23. Wechsler D. Manual for the Wechsler Memory Scale-revised. San Antonio: Psychological Corporation; 1987.
24. Delis D, Kaplan E, Kramer J, Ober B. California Verbal Learning Test-II. San Antonio: Psychological Corporation; 2000.
25. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test, Second ed. Philadelphia: Lea & Febiger; 1983.
26. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-revised. New York: Psychological Corporation; 1981.
27. Woodcock RW, Johnson MB. The Woodcock-Johnson Psycho-Educational Battery-revised. Texas: DLM Teaching Resources; 1990.
28. Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003; 16: 229-237.
29. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-2754.
30. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
31. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
32. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519.
33. 11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008; 39: 1027-1033.
34. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
35. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004; 19: 60-67.
36. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
37. 11C-PIB PET study. Neurology 2009; 73: 754-760.